Andrew Green Sells 1,493 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 1,493 shares of the company’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $26.02, for a total transaction of $38,847.86. Following the sale, the senior vice president directly owned 51,640 shares in the company, valued at $1,343,672.80. This trade represents a 2.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Artivion Stock Performance

Shares of Artivion stock opened at $25.59 on Friday. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. The business has a 50-day moving average price of $26.09 and a two-hundred day moving average price of $29.21. Artivion, Inc. has a 1-year low of $19.16 and a 1-year high of $48.25. The company has a market cap of $1.25 billion, a P/E ratio of -365.52 and a beta of 1.25.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%.The company had revenue of $125.76 million for the quarter, compared to the consensus estimate of $119.99 million. As a group, analysts anticipate that Artivion, Inc. will post 0.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a research report on Monday, June 1st. Needham & Company LLC reissued a “buy” rating and set a $44.00 price objective on shares of Artivion in a research report on Monday, July 20th. Wall Street Zen downgraded Artivion from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings lowered Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Canaccord Genuity Group upped their price target on Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Artivion has an average rating of “Moderate Buy” and a consensus target price of $44.83.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Verition Fund Management LLC grew its holdings in shares of Artivion by 1.6% during the third quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock valued at $716,000 after buying an additional 274 shares during the last quarter. Entropy Technologies LP lifted its position in Artivion by 6.0% in the 4th quarter. Entropy Technologies LP now owns 5,504 shares of the company’s stock valued at $251,000 after acquiring an additional 310 shares in the last quarter. Rockefeller Capital Management L.P. lifted its position in Artivion by 150.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after acquiring an additional 399 shares in the last quarter. Arizona State Retirement System boosted its stake in Artivion by 4.6% during the 4th quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock valued at $512,000 after purchasing an additional 494 shares during the last quarter. Finally, Amundi boosted its stake in Artivion by 7.5% during the 1st quarter. Amundi now owns 7,186 shares of the company’s stock valued at $263,000 after purchasing an additional 501 shares during the last quarter. 86.37% of the stock is owned by institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.